Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 4/20 | 0.48 |
| ▸ | FNTB | P49356 | 4/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526077 | 1.00 | ANPEP (0.58) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL29199142 | 0.98 | ANPEP (0.56) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL30137695 | 0.98 | ANPEP (0.56) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| Acrylic Acid SCHEMBL1876772 | 0.92 | ANPEP (0.51) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| SCHEMBL7265651 | 0.88 | ANPEP (0.55) | ANPEPLTA4HGAA | |
| SCHEMBL3649405 | 0.87 | HTT (0.55) | ANPEPGAAFNTAFNTB | |
| SCHEMBL3649406 | 0.87 | HTT (0.55) | ANPEPGAAFNTAFNTB | |
| Acrylic Acid SCHEMBL17975813 | 0.86 | GAA (0.46) | ANPEPLTA4HGAAALDH1A1NPSR1 | |
| SCHEMBL30402768 | 0.86 | FNTA (0.56) | ANPEPLTA4HALDH1A1FNTAFNTB | |
| Hydrochloric Acid SCHEMBL1886525 | 0.85 | HTT (0.54) | ANPEPGAAFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134196-A1 | ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | GMAX BIOPHARM LLC (CN) | 2019-05-09 | — | — | US | claimed |
| EP-3476864-A1 | ETAR ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Gmax Biopharm LLC (CN) | 2019-05-01 | — | — | EP | claimed |
| US-12594334-B2 | ETAR antibody, and pharmaceutical compositions and use thereof | GMAX BIOPHARM LLC. (CN) | 2026-04-07 | — | — | US | disclosed |
| CN-119954890-A | Optically pure small peptide chemiluminescent probe and application thereof in mycobacterium tuberculosis recognition | 广东工业大学 | 2025-05-09 | — | — | CN | disclosed |
| US-20230346932-A1 | ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | GMAX BIOPHARM LLC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20190134196-A1 | ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | GMAX BIOPHARM LLC (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3476864-A1 | ETAR ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Gmax Biopharm LLC (CN) | 2019-05-01 | — | — | EP | disclosed |
| EP-2598160-A2 | STABILIZATION OF FSH | Ferring BV (NL) | 2013-06-05 | — | — | EP | disclosed |
| CN-101597321-B | LHRH antagonist with long-acting low-histamine release side effect | INST PHARM & TOXICOLOGY AMMS | 2013-04-24 | — | — | CN | disclosed |
| WO-2012013742-A2 | STABILIZATION OF FSH | FERRING B.V. (NL) | 2012-02-02 | — | — | WO | disclosed |
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | ALLERGAN, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2185506-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| CN-101597321-A | The lhrh antagonist of long-acting low-histamine release side effect | INST PHARM & TOXICOLOGY AMMS (CN) | 2009-12-09 | — | — | CN | disclosed |
| WO-2009026407-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594334-B2 | ETAR antibody, and pharmaceutical compositions and use thereof | EDNRA, FLT1, VEGFA | ANPEP 793/4885LTA4H 3585/4885GAA 4809/4885 |
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | S1PR1, S1PR2, S1PR3 | ANPEP 1641/4885LTA4H 557/4885GAA 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.